Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Carson

Showing results (291-300 of 364) with videos related to

Pageof 37
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2013
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphomaA M Evens, K R Carson, J Kolesar, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 11, 1991
Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in ratsC G Yeh, H C Marsh, G R Carson, et al.
Journal of the American College of Surgeons|February 27, 2016
Transforming Patient Value: Comparison of Hospital, Surgical, and General Surgery PatientsHenry A Pitt, Ella Tsypenyuk, Susan L Freeman, et al.
Clinical Genitourinary Cancer|July 26, 2023
Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or EnzalutamideForest Riekhof, Yan Yan, Charles L Bennett, et al.
Science (New York, N.Y.)|July 13, 1990
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosisH F Weisman, T Bartow, M K Leppo, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2024
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell LymphomasNicole Foley, Peter A Riedell, Nancy L Bartlett, et al.
Journal of Immunological Methods|September 15, 1993
Characterization of monoclonal antibodies specific for the V beta 3 family of the human T cell receptor generated using soluble TCR beta-chainS D Calaman, G R Carson, L D Henry, et al.
Journal of Medicinal Chemistry|March 1, 1988
2-Ethynylbenzenealkanamines. A new class of calcium entry blockersJ R Carson, H R Almond, M D Brannan, et al.
Molecular Metabolism|June 11, 2025
Methylglyoxal-induced RNA modifications decrease RNA stability and translation and are associated with type 2 diabetesEdwin De Jesus Lopez Gonzalez, Seigmund Wai Tsuen Lai, Kelani Sun, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
Parallel methods for the preparation and SAR exploration of N-ethyl-4-[(8-alkyl-8-aza-bicyclo[3.2.1]oct-3-ylidene)-aryl-methyl]-benzamides, powerful mu and delta opioid agonistsSteven J Coats, Mark J Schulz, John R Carson, et al.
Pageof 37

Showing results (291-300 of 364) with videos related to

Sort By:
Pageof 37
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2013
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphomaA M Evens, K R Carson, J Kolesar, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 11, 1991
Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in ratsC G Yeh, H C Marsh, G R Carson, et al.
Journal of the American College of Surgeons|February 27, 2016
Transforming Patient Value: Comparison of Hospital, Surgical, and General Surgery PatientsHenry A Pitt, Ella Tsypenyuk, Susan L Freeman, et al.
Clinical Genitourinary Cancer|July 26, 2023
Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or EnzalutamideForest Riekhof, Yan Yan, Charles L Bennett, et al.
Science (New York, N.Y.)|July 13, 1990
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosisH F Weisman, T Bartow, M K Leppo, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2024
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell LymphomasNicole Foley, Peter A Riedell, Nancy L Bartlett, et al.
Journal of Immunological Methods|September 15, 1993
Characterization of monoclonal antibodies specific for the V beta 3 family of the human T cell receptor generated using soluble TCR beta-chainS D Calaman, G R Carson, L D Henry, et al.
Journal of Medicinal Chemistry|March 1, 1988
2-Ethynylbenzenealkanamines. A new class of calcium entry blockersJ R Carson, H R Almond, M D Brannan, et al.
Molecular Metabolism|June 11, 2025
Methylglyoxal-induced RNA modifications decrease RNA stability and translation and are associated with type 2 diabetesEdwin De Jesus Lopez Gonzalez, Seigmund Wai Tsuen Lai, Kelani Sun, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
Parallel methods for the preparation and SAR exploration of N-ethyl-4-[(8-alkyl-8-aza-bicyclo[3.2.1]oct-3-ylidene)-aryl-methyl]-benzamides, powerful mu and delta opioid agonistsSteven J Coats, Mark J Schulz, John R Carson, et al.
Pageof 37